The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Durable responses to imatinib in patients with PDGFRB fusion gene–positive and BCR-ABL–negative chronic myeloproliferative disorders
Open accessAbstract
Fusion genes derived from the platelet-derived growth factor receptor beta (PDGFRB) or alpha (PDGFRA) play an important role in the pathogenesis of BCR-ABL–negative chronic myeloproliferative disorders (CMPDs). These fusion genes encode constitutively activated receptor tyrosine kinases that can be inhibited by imatinib. Twelve patients with BCR-ABL–negative CMPDs and reciprocal translocations involving PDGFRB received imatinib for a median of 47 months (range, 0.1-60 months). Eleven had prompt responses with normalization of peripheral-blood cell counts and disappearance of eosinophilia; 10 had complete resolution of cytogenetic abnormalities and decrease or disappearance of fusion transcripts as measured by reverse transcriptase–polymerase chain reaction (RT-PCR). Updates were sought from 8 further patients previously described in the literature; prompt responses were described in 7 and persist in 6. Our data show that durable hematologic and cytogenetic responses are achieved with imatinib in patients with PDGFRB fusion–positive, BCR-ABL–negative CMPDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kaminski, W. E., Lindahl, P., Lin, N. L., Broudy, V. C., Crosby, J. R., Hellström, M., Swolin, B., Bowen-Pope, D. F., Martin, P. J., Ross, R., et al. (2001) · Blood · doi:10.1182/blood.v97.7.1990 · Cited by 77
Cited by
Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
Lovly, C. M., Gupta, A., Lipson, D., Otto, G., Brennan, T., Chung, C. T., Borinstein, S. C., Ross, J. S., Stephens, P. J., Miller, V. A., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0377 · Cited by 455
Chromosomal Abnormalities in Cancer
Fröhling, S., & Döhner, H. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0803109 · Cited by 229
Analysis of CD74 Occurrence in Oncogenic Fusion Proteins
(2023) · doi:10.3390/ijms242115981 · Cited by 14
OpenDVP: an experimental and computational framework for community-empowered deep visual proteomics
Nimo, J., Fritzsche, S., Valdes, D. S., Trinh, M., Pentimalli, T., Klingeberg, M., Schallenberg, S., Klauschen, F., Herse, F., Florian, S., et al. (2026) · Nature Methods · doi:10.1038/s41592-026-03262-z
Metadata
- Authors
- David, M., Cross, N. C. P., Burgstaller, S., Chase, A., Curtis, C., Dang, R., Gardembas, M., Goldman, J. M., Grand, F., Hughes, G., Huguet, F., Lavender, L., McArthur, G. A., Mahon, F. X., Massimini, G., Melo, J., Rousselot, P., Russell-Jones, R. J., Seymour, J. F., Smith, G., Stark, A., Waghorn, K., Nikolova, Z., & Apperley, J. F.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-09-07
- Volume
- 109
- Issue
- 1
- Pages
- 61-64
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2075213943
- Cited by
- 172
- References
- 1
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Durable responses to imatinib in patients with PDGFRB fusion gene–positive and BCR-ABL–negative chronic myeloproliferative disorders. https://app.cochat.ai/papers/10.1182/blood-2006-05-024828
- The paper
- David, M., Cross, N. C. P., Burgstaller, S., Chase, A., Curtis, C., Dang, R., Gardembas, M., Goldman, J. M., Grand, F., Hughes, G., Huguet, F., Lavender, L., McArthur, G. A., Mahon, F. X., Massimini, G., Melo, J., Rousselot, P., Russell-Jones, R. J., Seymour, J. F., . . . Apperley, J. F. (2007). Durable responses to imatinib in patients with PDGFRB fusion gene–positive and BCR-ABL–negative chronic myeloproliferative disorders. Blood. https://doi.org/10.1182/blood-2006-05-024828
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.